AstraZeneca and Merck & Co Inc enter into worldwide licensing agreement for Merck's oral small molecule inhibitor of WEE1 kinase (MK-1775)

AstraZeneca and Merck & Co Inc , known outside the United States and Canada as MSD,  today announced a worldwide licensing agreement for Merck's oral small molecule inhibitor of WEE1 kinase (MK-1775). MK-1775 is currently being evaluated in Phase IIa clinical studies in combination with standard of care therapies for the treatment of patients with certain types of ovarian cancer.